DeepMed Research

Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Phase 1

Withdrawn

Conditions: Leukemia
Myelodysplastic Syndromes
Lymphoma

First Posted Date: 2004-02-16

Last Posted Date: 2020-07-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00004114

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab

First Posted Date: 2004-02-12

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT00004889

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 5 locations

Radiation Therapy Following Surgery to Remove Brain Metastases

Not Applicable

Completed

Conditions: Metastatic Cancer

First Posted Date: 2004-02-06

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT00003320

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer

Phase 2

Conditions: Ovarian Cancer

First Posted Date: 2004-02-04

Last Posted Date: 2013-12-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00021385

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Phase 2

Conditions: Myelodysplastic Syndromes

First Posted Date: 2004-01-14

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00022321

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Phase 3

Completed

Conditions: Gastric Cancer
Esophageal Cancer

Interventions: Biological: G17DT Immunogen
Drug: cisplatin
Drug: fluorouracil

First Posted Date: 2004-01-08

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT00020787

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain

Phase 2

Completed

Conditions: Metastatic Cancer

Interventions: Drug: temozolomide

First Posted Date: 2004-01-01

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT00012116

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors

Phase 2

Withdrawn

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-12-16

Last Posted Date: 2012-10-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00005083

Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-12-02

Last Posted Date: 2009-02-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00003409

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-11-06

Last Posted Date: 2013-01-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT00071968

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy